Arca
Skip to content
Tools
Tools

MAOA: Amine oxidase [flavin-containing] A

Catalyzes the oxidative deamination of primary and some secondary amine such as neurotransmitters, with concomitant reduction of oxygen to hydrogen peroxide and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues.

  • Drugs that act on it: 5
  • Approved: 4
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on MAOA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4
  • Other 1

Approved4

  • Minaprine
  • Moclobemide
  • Proxibarbal
  • Toloxatone

Phase 30

    Phase 21

    • Indantadol

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 5 act as: Monoamine oxidase A inhibitor; the rest name their own mechanism.
      MinaprineWithdrawnApprovedAstraZeneca PharmaceuticalsSmall moleculeInhibitor1
      MoclobemideApproved—Small moleculeInhibitor1
      ProxibarbalWithdrawnApproved—Small moleculeActivatorMonoamine oxidase A activator0
      ToloxatoneApproved—Small moleculeInhibitor0
      IndantadolPhase 2Vernalis (R&D) LtdOtherInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
      A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerMinaprinePhase 2Active, not recruitingAstraZenecaJan 27, 2025
      Efficacy of Hydroxyzine for Patients With Panic DisorderMoclobemidePhase 4Not yet recruitingSultan Qaboos UniversityFeb 21, 2023

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Brunner syndrome0.79
      • Hypertensive disorder0.46
      • Hereditary disease0.45
      • Mental disorder0.38
      • Melancholia0.37
      • Autism0.34
      • Intellectual disability0.31
      • Drooling0.26
      • Internet addiction disorder0.11
      • Posterior cortical atrophy0.11

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1951, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P21397, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.